These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15673131)

  • 1. Hepatic safety and HAART.
    McGovern B
    J Int Assoc Physicians AIDS Care (Chic); 2004 Nov; 3 Suppl 2():S24-40. PubMed ID: 15673131
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity profile of HAART.
    TreatmentUpdate; 2001; 13(7):6-7. PubMed ID: 11794864
    [No Abstract]   [Full Text] [Related]  

  • 4. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?
    Ingiliz P; Benhamou Y
    J HIV Ther; 2009 Mar; 14(1):3-7. PubMed ID: 19731558
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
    French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
    Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management.
    Manfredi R
    AIDS; 2003 Oct; 17(15):2253-6. PubMed ID: 14523283
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part I.
    Boyle BA
    AIDS Read; 2001 Jul; 11(7):354-5, 359-61, 363. PubMed ID: 11494705
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic liver disease in the human immunodeficiency virus patient.
    Acharya C; Dharel N; Sterling RK
    Clin Liver Dis; 2015 Feb; 19(1):1-22. PubMed ID: 25454294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting to the HAART of insulin resistance.
    Nolan D; Mallal S
    AIDS; 2001 Oct; 15(15):2037-41. PubMed ID: 11600834
    [No Abstract]   [Full Text] [Related]  

  • 11. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology.
    Sonderup MW; Wainwright HC
    Gastroenterol Clin North Am; 2017 Jun; 46(2):327-343. PubMed ID: 28506368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 13. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?
    Gilleece Y; Nelson M
    J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
    [No Abstract]   [Full Text] [Related]  

  • 15. [HIV therapy: toxic liver injuries caused by protease inhibitors?].
    Kunde K
    Dtsch Med Wochenschr; 2000 Mar; 125(12):A12-3. PubMed ID: 10777343
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report.
    Jülg B; Bogner JR; Goebel FD
    AIDS; 2006 Jul; 20(11):1563. PubMed ID: 16847416
    [No Abstract]   [Full Text] [Related]  

  • 18. HAART-related nephropathies in HIV-infected patients.
    Daugas E; Rougier JP; Hill G
    Kidney Int; 2005 Feb; 67(2):393-403. PubMed ID: 15673287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.
    Tuma P; Medrano J; Resino S; Vispo E; Madejón A; Sánchez-Piedra C; Rivas P; Labarga P; Martín-Carbonero L; Barreiro P; Soriano V
    Antivir Ther; 2010; 15(6):881-6. PubMed ID: 20834100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.